A Zenith Capital nomeou o advogado Bryan Ede, de Calgary, para o seu conselho, substituindo o diretor aposentado Dr. Norman Wong. Zenith Capital appointed Calgary lawyer Bryan Ede to its board, replacing retiring director Dr. Norman Wong.

A Zenith Capital Corp. nomeou Bryan R. Ede, J.D., para seu Conselho de Administração em 3 de março de 2026, sucedendo o diretor aposentado Dr. Norman Wong, M.D. Zenith Capital Corp. appointed Bryan R. Ede, J.D., to its Board of Directors on March 3, 2026, succeeding retiring director Dr. Norman Wong, M.D. Ede, um advogado comercial com sede em Calgary com mais de 27 anos de experiência, anteriormente atuou como sócio da McMillan LLP e Miller Thomson LLP, desempenhando cargos de liderança, incluindo Calgary Managing Partner e Chair of Legal Practice Groups. Ede, a Calgary-based commercial lawyer with over 27 years of experience, previously served as an equity partner at McMillan LLP and Miller Thomson LLP, holding leadership roles including Calgary Managing Partner and Chair of legal practice groups. Sua experiência abrange saúde, imóveis, varejo e petróleo e gás, com foco em questões comerciais transacionais e estratégicas. His expertise spans healthcare, real estate, retail, and oil and gas, with a focus on transactional and strategic business matters. A empresa, cuja subsidiária Zenith Epigenetics Ltd. está desenvolvendo terapias contra o câncer, incluindo ZEN-3694 em ensaios clínicos, observou que suas declarações prospectivas estão sujeitas a riscos e incertezas. The company, whose subsidiary Zenith Epigenetics Ltd. is developing cancer therapeutics, including ZEN-3694 in clinical trials, noted that its forward-looking statements are subject to risks and uncertainties.